Community Resources

bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges

Date: 
Nov 7, 2018
Author(s): 
Simon Collins, HIV i-Base


The R4P2018 conference included a wealth of studies looking at broadly neutralising monoclonal antibody (bNAbs) for HIV prevention.

A selection of these studies reported below shows the complexities of this research which is important given large-scale studies are already ongoing.

Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP

Date: 
Nov 1, 2018
Author(s): 
Simon Collins, HIV i-Base


The properties of long-acting PrEP drugs that reduce the need for daily dosing also presents a new set of challenges if and when people decide to stop.

When LA drugs are used for treatment, this is less of a problem, as HIV positive people will usually be switching to an alternative drug combination.

Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections

Date: 
Aug 24, 2018
Author(s): 
Simon Collins, HIV i-Base


On 15 August 2018, top-line results from the phase 3 ATLAS study reported that monthly injections with the dual long-acting formulation cabotegravir/rilpivirine were non-inferior as a switch option compared to remaining on triple-drug ART.

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study randomised 570 HIV positive adults who had been virally suppressed for more than six months on their first or second HIV combination.

Long-acting ART for children is a deferred priority despite achievable dosing

Date: 
Nov 28, 2017
Author(s): 
Polly Clayden, HIV i-Base


Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted for different weight bands in children and adolescents.

Long-acting injectable antiretrovirals could be future alternatives to oral formulations and might help to address adherence. There is great interest in the potential use of these formulations in the treatment of paediatric HIV.

Pages